2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Gene Editing, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Gene Therapy, Workforce, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, GVHD, GVD, Immunodeficiency, Neutropenia, White Blood Cell Disorders, Research, Fundamental Science, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

6126 Estimating country-specific maximum justifiable acquisition prices for gene therapy in sickle cell disease: A seven-country cost-effectiveness analysis

Dick Nchang, BA, Ishaan Vaswani, MS, BA2, George Morgan, MSc3, Nowah Afangbedji, PhD4, Matthew Hebden Porteus, MD, PhD5
1 Stanford University, Stanford, California, United States
2 Stanford University, Stanford, United States
3 DHT.health, Clitheroe, United Kingdom, Lancaster University, Lancaster, United Kingdom
4 Stanford University, Stanford, California, United States
5 Stanford University, Stanford, California, United States

Introduction

Sickle cell disease (SCD) imposes a substantial clinical and economic burden across many lower- and middle-income countries (LMICs), where access to curative therapies remains limited. While gene therapy (GTx) offers the potential for durable remission, there are no country-specific estimates of the prices at which it represents good value for money. We estimated the maximum justifiable acquisition price of one-time GTx across seven high-burden countries using a common cost-effectiveness framework to support value-based pricing and future access strategies.

 

Methods 

Country-specific cost-effectiveness models were developed for Nigeria, Ghana, Kenya, Tanzania, Cameroon, Democratic Republic of Congo and India. Separate three-state Markov models compared lifelong hydroxyurea (HU: Mild, Severe, Dead) with one-time GTx (Remission, Sick, Dead), using monthly cycles over a 55-year horizon from age 12 years. Clinical efficacy was informed by the pivotal Casgevy trial, while mortality incorporated country-specific life tables with excess SCD mortality. Outcomes were measured in quality-adjusted life years (QALYs). Costs (2024 USD) were estimated from a restricted societal perspective using the best available country-specific evidence, supplemented by income-scaled estimates where necessary. Costs and outcomes were discounted at 3% annually. The primary outcome was the maximum justifiable acquisition price (c*) at willingness-to-pay thresholds of 1× and 3× GDP per capita and, where available, country-specific health opportunity cost thresholds. Probabilistic (5,000 simulations), one-way sensitivity and scenario analyses assessed parameter uncertainty.

 

Results 

GTx generated consistent health gains across all seven countries, with incremental QALYs ranging from 10.59 to 11.39. Maximum justifiable acquisition prices (c*) at the 1× GDP per capita threshold ranged from $11,539 (Democratic Republic of Congo) to $44,198 (India), increasing to $25,682-$99,646 at the 3× GDP threshold. Probabilistic mean estimates remained within 1% of deterministic values across all countries. Nigeria, the only country with peer-reviewed national SCD costing, demonstrated the narrowest uncertainty (95% CI: $26,537-$49,139), whereas wider intervals were observed where income-scaled costing was required. Replacing income-scaled estimates with published national costing reduced c* by 23% in India and 28% in Ghana without changing the overall conclusions. Across all durability scenarios, c* remained positive, retaining 64-65% of base-case values under a 2% annual loss of response. Compared with the only published LMIC delivery cost estimate ($48,809), no country exceeded total delivery costs at the 1× GDP threshold, whereas five of seven countries exceeded this benchmark at the 3× GDP threshold.

 

Conclusions 

GTx delivers substantial health gains across high-burden LMICs. Estimating country-specific maximum justifiable acquisition prices provides evidence-based benchmarks for value-based pricing and transparent negotiating anchors for manufacturers, governments and procurement agencies. The affordability gap varied widely, narrowing to $4,611 in India while remaining substantial in the lowest-income settings, suggesting that tiered and negotiated pricing could materially improve access where headroom is greatest.

Dick Nchang, BA: No relevant conflicts of interest to declare.